Compare Pfizer Inc (PFE) vs Veritone Inc (VERI) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

VERI trades at $1.05, up 2.94% today, but remains in a bearish technical trend with negative earnings and cash flow. The company reported a net loss of $111.73M in 2025, with revenue of $92.19M, and faces multiple securities class action lawsuits. Analyst ratings are split evenly between Buy and Hold, with a minority Sell rating, reflecting uncertainty amid financial challenges and legal overhangs.

The outlook is highly speculative due to persistent losses, negative margins, and legal risks. While the low P/S ratio of 0.87 may attract value hunters, the stock carries significant downside risk from operational cash burn and potential settlement costs. Investors should weigh the speculative potential against substantial financial and litigation headwinds.